德国甲状腺医生对甲状腺功能减退和甲状腺功能正常患者使用甲状腺激素的问卷调查:论文(欧洲专家治疗甲状腺功能减退:一项国际调查)合作。

I. Vardarli, T. Brandenburg, L. Hegedüs, R. Attanasio, E. Nagy, E. Papini, P. Perros, F. Weidemann, K. Herrmann, D. Führer
{"title":"德国甲状腺医生对甲状腺功能减退和甲状腺功能正常患者使用甲状腺激素的问卷调查:论文(欧洲专家治疗甲状腺功能减退:一项国际调查)合作。","authors":"I. Vardarli, T. Brandenburg, L. Hegedüs, R. Attanasio, E. Nagy, E. Papini, P. Perros, F. Weidemann, K. Herrmann, D. Führer","doi":"10.1055/a-1832-0644","DOIUrl":null,"url":null,"abstract":"OBJECTIVE\nTo identify the attitudes of German thyroid specialists towards the clinical treatment of hypothyroidism using thyroid hormones (TH).\n\n\nMETHODS\nAll members of the thyroid section of the German Endocrine Society (DGE) were e-mailed an invitation to participate in a web-based survey about substitution with TH.\n\n\nRESULTS\nOut of 206 members of the DGE's thyroid section, 163 (79.1%) responses were received and included in the analysis. Of responding members, 98.6% used levothyroxine (LT4) as the treatment of choice, and 45.4% also prescribed combination therapy with liothyronine (LT4+LT3) in their clinical practice (p<0.001). LT4+LT3 combination was favored in patients with persistent hypothyroidism symptoms despite biochemical euthyroidism on LT4 treatment (p<0.001). Of all respondents, 26.4% never indicated TH therapy for euthyroid patients (p<0.001), while the remainder would consider THs for one or more indications (62.9% for euthyroid infertile women with high anti-thyroid antibody levels (p<0.001), 7.1% in patients with severe hypercholesterolemia, as complementary treatment (p=0.007), and 57.1% in patients with simple goiter (p<0.001)). In conditions that could interfere with LT4 absorption, most respondents still preferred tablets and did not expect a significant difference when switching from one LT4 formulation to another.\n\n\nCONCLUSION\nFor German thyroid specialists, LT4 is the treatment of choice for hypothyroidism. Combination therapy with LT4+LT3 was considered for patients with persistent symptoms. Even in conditions that could affect bioavailability, German thyroid specialists prefer LT4 tablets rather than other LT4 formulations, such as liquid or soft-gel capsules. The widespread use of thyroid hormone for non-hypothyroid conditions is not consistent with current evidence and needs further study.","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":"{\"title\":\"A Questionnaire Survey of German Thyroidologists on the Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: The THESIS (Treatment of Hypothyroidism in Europe by Specialists: An International Survey) Collaborative.\",\"authors\":\"I. Vardarli, T. Brandenburg, L. Hegedüs, R. Attanasio, E. Nagy, E. Papini, P. Perros, F. Weidemann, K. Herrmann, D. Führer\",\"doi\":\"10.1055/a-1832-0644\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"OBJECTIVE\\nTo identify the attitudes of German thyroid specialists towards the clinical treatment of hypothyroidism using thyroid hormones (TH).\\n\\n\\nMETHODS\\nAll members of the thyroid section of the German Endocrine Society (DGE) were e-mailed an invitation to participate in a web-based survey about substitution with TH.\\n\\n\\nRESULTS\\nOut of 206 members of the DGE's thyroid section, 163 (79.1%) responses were received and included in the analysis. Of responding members, 98.6% used levothyroxine (LT4) as the treatment of choice, and 45.4% also prescribed combination therapy with liothyronine (LT4+LT3) in their clinical practice (p<0.001). LT4+LT3 combination was favored in patients with persistent hypothyroidism symptoms despite biochemical euthyroidism on LT4 treatment (p<0.001). Of all respondents, 26.4% never indicated TH therapy for euthyroid patients (p<0.001), while the remainder would consider THs for one or more indications (62.9% for euthyroid infertile women with high anti-thyroid antibody levels (p<0.001), 7.1% in patients with severe hypercholesterolemia, as complementary treatment (p=0.007), and 57.1% in patients with simple goiter (p<0.001)). In conditions that could interfere with LT4 absorption, most respondents still preferred tablets and did not expect a significant difference when switching from one LT4 formulation to another.\\n\\n\\nCONCLUSION\\nFor German thyroid specialists, LT4 is the treatment of choice for hypothyroidism. Combination therapy with LT4+LT3 was considered for patients with persistent symptoms. Even in conditions that could affect bioavailability, German thyroid specialists prefer LT4 tablets rather than other LT4 formulations, such as liquid or soft-gel capsules. The widespread use of thyroid hormone for non-hypothyroid conditions is not consistent with current evidence and needs further study.\",\"PeriodicalId\":94001,\"journal\":{\"name\":\"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-05-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/a-1832-0644\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-1832-0644","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

摘要

目的了解德国甲状腺专科医生对临床应用甲状腺激素治疗甲状腺功能减退症的态度。方法通过电子邮件邀请德国内分泌学会(DGE)甲状腺分会的所有成员参加一项关于TH替代的网络调查。结果在DGE甲状腺科206名成员中,收到163份(79.1%)回复并纳入分析。在回应的成员中,98.6%的人在临床实践中选择左旋甲状腺素(LT4)作为治疗选择,45.4%的人在临床实践中也处方与碘甲状腺原氨酸(LT4+LT3)联合治疗(p<0.001)。LT4+LT3联合治疗虽有生化甲状腺功能亢进,但仍有持续甲状腺功能减退症状的患者更受青睐(p<0.001)。在所有应答者中,26.4%的人从未对甲状腺功能正常的患者进行过甲状腺激素治疗(p<0.001),而其余的人会考虑将甲状腺激素治疗用于一种或多种适应症(62.9%的抗甲状腺抗体水平高的甲状腺功能正常的不孕妇女(p<0.001), 7.1%的患者患有严重的高胆固醇血症,作为补充治疗(p=0.007), 57.1%的患者患有单纯甲状腺肿(p<0.001))。在可能干扰LT4吸收的条件下,大多数应答者仍然倾向于片剂,并且在从一种LT4制剂切换到另一种制剂时,并不期望有显着差异。结论对于德国甲状腺专科医生来说,LT4是甲状腺功能减退的首选治疗方法。对于持续症状的患者,考虑LT4+LT3联合治疗。即使在可能影响生物利用度的情况下,德国甲状腺专家也更喜欢LT4片剂,而不是其他LT4制剂,如液体或软凝胶胶囊。甲状腺激素在非甲状腺功能减退疾病中的广泛应用与目前的证据不一致,需要进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
A Questionnaire Survey of German Thyroidologists on the Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: The THESIS (Treatment of Hypothyroidism in Europe by Specialists: An International Survey) Collaborative.
OBJECTIVE To identify the attitudes of German thyroid specialists towards the clinical treatment of hypothyroidism using thyroid hormones (TH). METHODS All members of the thyroid section of the German Endocrine Society (DGE) were e-mailed an invitation to participate in a web-based survey about substitution with TH. RESULTS Out of 206 members of the DGE's thyroid section, 163 (79.1%) responses were received and included in the analysis. Of responding members, 98.6% used levothyroxine (LT4) as the treatment of choice, and 45.4% also prescribed combination therapy with liothyronine (LT4+LT3) in their clinical practice (p<0.001). LT4+LT3 combination was favored in patients with persistent hypothyroidism symptoms despite biochemical euthyroidism on LT4 treatment (p<0.001). Of all respondents, 26.4% never indicated TH therapy for euthyroid patients (p<0.001), while the remainder would consider THs for one or more indications (62.9% for euthyroid infertile women with high anti-thyroid antibody levels (p<0.001), 7.1% in patients with severe hypercholesterolemia, as complementary treatment (p=0.007), and 57.1% in patients with simple goiter (p<0.001)). In conditions that could interfere with LT4 absorption, most respondents still preferred tablets and did not expect a significant difference when switching from one LT4 formulation to another. CONCLUSION For German thyroid specialists, LT4 is the treatment of choice for hypothyroidism. Combination therapy with LT4+LT3 was considered for patients with persistent symptoms. Even in conditions that could affect bioavailability, German thyroid specialists prefer LT4 tablets rather than other LT4 formulations, such as liquid or soft-gel capsules. The widespread use of thyroid hormone for non-hypothyroid conditions is not consistent with current evidence and needs further study.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Novel treatment options in patients with maturity onset diabetes of the young. 21-hydroxylase deficiency detected in neonatal screening: high probability of false negativity in late onset form. Oridonin Attenuates Diabetes‑induced Renal Fibrosis via the Inhibition of TXNIP/NLRP3 and NF‑κB Pathways by Activating PPARγ in Rats. Skeletal Effects of a Prolonged Oral Metformin Treatment in Adult Wistar Rats. From Nelson's Syndrome to Corticotroph Tumor Progression Speed: An Update.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1